Company research
HeartBeam, Inc.
CIK 1779372Updated Sep 27, 2026
BEAT price & chart
Loading TradingView…
NASDAQ:BEAT on TradingView ↗About the company
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
4 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
DEFA14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,843,000Source | 3,276,000Source | 17,131,000Source | 4,039,000Source |
| Property, Plant and Equipment, NetUSD | 1,102,000Source | 450,000Source | 256,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,380,000Source | 2,377,000Source | 16,189,000Source | 3,594,000Source |
| Inventory, NetUSD | 103,000Source | — | — | — |
| Assets, CurrentUSD | 4,685,000Source | 2,770,000Source | 16,825,000Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 202,000Source | 393,000Source | 636,000Source | 445,000Source |
| Other Assets, NoncurrentUSD | 56,000Source | 56,000Source | 50,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,240,000Source | 1,622,000Source | 1,194,000Source | 1,665,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 3,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 79,887,000Source | 57,924,000Source | 52,759,000Source | 24,559,000Source |
| Retained Earnings (Accumulated Deficit)USD | -77,288,000Source | -56,273,000Source | -36,825,000Source | -22,186,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,603,000Source | 1,654,000Source | 15,937,000Source | 2,374,000Source |
| Liabilities and EquityUSD | 5,843,000Source | 3,276,000Source | 17,131,000Source | 4,039,000Source |
| Current liabilities: | ||||
| Accounts Payable, CurrentUSD | 1,053,000Source | 531,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,187,000Source | 1,091,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 4,400,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,147,000Source | 4,299,000Source | 3,208,000Source | 1,120,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 103,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,988,000Source | -14,471,000Source | -12,093,000Source | -9,948,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -600,000Source | -201,000Source | -256,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 600,000Source | 201,000Source | 256,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,591,000Source | 866,000Source | 24,994,000Source | 350,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,003,000Source | -13,806,000Source | 12,645,000Source | -9,598,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,436,000Source | 2,433,000Source | 16,239,000Source | 3,594,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 0Source | 0Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | 5,146,893Source | 4,298,736Source | 3,208,076Source | 1,119,817Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 4,400,000Source | — | — | — |
| DepreciationUSD | 40,000Source | 7,000Source | — | — |
| General and Administrative ExpenseUSD | 7,689,000Source | 8,836,000Source | 8,516,000Source | 7,354,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -21,015,000,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -21,015,000Source | -19,448,000Source | -14,639,000Source | -12,962,000Source |
| Nonoperating Income (Expense)USD | 124,000Source | 439,000Source | 675,000Source | 69,000Source |
| Operating ExpensesUSD | 21,139,000Source | 19,887,000Source | 15,314,000Source | 13,031,000Source |
| Other Nonoperating Income (Expense)USD | 2,000Source | -7,000Source | 0Source | 3,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | 16,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | 730,000Source | 24,764,000Source | 348,000Source |
| Proceeds from Stock Options ExercisedUSD | 13,000Source | 136,000Source | 214,000Source | 2,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -21,139,000Source | -19,887,000Source | -15,314,000Source | -13,031,000Source |
| Other Nonoperating Income (Expense)USD | 2,000Source | -7,000Source | 0Source | 3,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -21,015,000Source | -19,448,000Source | -14,639,000Source | -12,962,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -21,015,000Source | -19,448,000Source | -14,639,000Source | -12,962,000Source |
| Earnings Per Share, BasicUSD per share | -0.62Source | -0.73Source | -0.72Source | -1.59Source |
| Earnings Per Share, DilutedUSD per share | -0.62Source | -0.73Source | -0.72Source | -1.59Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 33,710,095Source | 26,645,228Source | 20,333,280Source | 8,168,516Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 33,710,095Source | 26,645,228Source | 20,333,280Source | 8,168,516Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 7,689,000Source | 8,836,000Source | 8,516,000Source | 7,354,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -21,015,000,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -21,015,000,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 122,000Source | 446,000Source | 675,000Source | 66,000Source |
| Nonoperating Income (Expense)USD | 124,000Source | 439,000Source | 675,000Source | 69,000Source |
| Operating ExpensesUSD | 21,139,000Source | 19,887,000Source | 15,314,000Source | 13,031,000Source |
| Other Cost and Expense, OperatingUSD | 700,000Source | — | — | — |
| Research and Development ExpenseUSD | 13,450,000Source | 11,051,000Source | 6,798,000Source | 5,677,000Source |
Filing attachments
ea029584901ex99-1.htm · 8-K · 2026-06-24
EX-99.1 2 ea029584901ex99-1.htm PRESS RELEASE OF HEARTBEAM, INC. ISSUED ON JUNE 24, 2026 Exhibit 99.1 HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating w…
Read attachment ↗ea028665501ex4-1.htm · 8-K · 2026-04-16
EX-4.1 3 ea028665501ex4-1.htm FORM OF UNDERWRITER WARRANT Exhibit 4.1 REPRESENTATIVE’S PURCHASE WARRANT heartbeam, INC. Warrant Shares: 625,000 Issue Date: April 16, 2026 ─────────────────────────────────────────────────────────── This REPRESENTATIVE’S PURCHASE WARRANT (the “Warrant”) certifies that, for value received, American Capital Partners, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter…
Read attachment ↗ea028665501ex99-1.htm · 8-K · 2026-04-16
EX-99.1 6 ea028665501ex99-1.htm PRESS RELEASE DATED APRIL 14, 2026 (LAUNCH PRESS RELEASE) Exhibit 99.1 HeartBeam Announces Proposed Public Offering of Common Stock SANTA CLARA, CA - April 14, 2026 - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the securities to b…
Read attachment ↗ea028665501ex99-2.htm · 8-K · 2026-04-16
EX-99.2 7 ea028665501ex99-2.htm PRESS RELEASE DATED APRIL 14, 2026 (PRICING PRESS RELEASE) Exhibit 99.2 HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company’s executive leadership, board members, and existing investors SANTA CLARA, CA - April 14, 2026 - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardia…
Read attachment ↗